Abstract
Venous thromboembolism (VTE) is due to its incidence, morbidity and mortality an important global socioeconomical problem. Antithrombotic prevention and treatment are one of the most common areas in moderne medicine.
TEN is still the frequent causes of mortality and morbidity. We are currently used in this field heparins, pentasaccharide and warfarin.
Warfarin despites undoubted effect, especially for its interindividual variability, the risk of drug and food interactions and a narrow therapeutic window. The development of new, effective oral anticoagulants (NOAC) focused mainly on direct thrombin inhibitors and direct factor Xa inhibitor.
From the first group is used in several indications in the Czech Republic dabigatran etexilate (Pradaxa).